Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
SYMLIN (pramlintide acetate) is a subcutaneous injectable small-molecule amylin analog approved in 2005 for patients with type 1 and type 2 diabetes. It slows gastric emptying, suppresses glucagon secretion, and reduces postprandial glucose excursions when used adjunctively with insulin. The drug addresses a specific niche in diabetes management for patients requiring additional glycemic control beyond insulin monotherapy.
As LOE approaches, the brand team is likely focused on lifecycle extension and defensive strategies rather than growth initiatives, with smaller commercial footprint than peak-stage products.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Worked on SYMLIN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SYMLIN roles are primarily focused on defensive commercialization and maintaining existing market share in a declining phase, with limited upside career growth potential. Professionals joining this team should expect to develop deep expertise in mature-asset management, payer negotiations, and market-access strategy rather than launch or growth-stage experiences.